摘要
胃癌目前仍是第二大癌症死因,总生存率为15％-20％。手术仍然是可切除胃癌的根治性治疗手段,近来的meta分析表明辅助放化疗可使患者临床受益,但辅助化疗作为常规治疗还缺乏结论性的证据。新辅助化疗对局部晚期胃癌降低分期是可行的,进一步研究正在进行中。对于晚期胃癌,姑息化疗可使中位生存期提高到7.5-12个月。含CPT-11、紫杉类的化疗方案能进一步提高化疗有效率,化疗联合新靶向治疗药物将为胃癌的治疗开辟另一途径。
Gastric cancer is still responsible for the second leading cause of cancer death, accounting for 15% -20% of overall survival rate. Surgery is the radical approach to resectable lesion. Recent meta- analysis indicated that adjuvant radiochemotherapy may be of benefit to patients with gastric cancer, but adjuvant chemotherapy show lack of concluded evidence as a routine treatment modality. Primary chemotherapy may be performed to downgrade stage in local advanced gastric cancer and further investigation is under the way. Palliative chemotherapy can increase median survival time to 7.5 - 12 months in advanced gastric cancer. Regimens containing CPT-11 and taxanens can improve further response rates. Chemotherapy in combination with new targeted treatment drug will provide a promising method in the treatment of gastric cancer.
出处
《癌症进展》
2004年第2期88-93,共6页
Oncology Progress
关键词
胃癌
辅助放化疗
新辅助化疗
姑息化疗
靶向治疗
gastric cancer adjuvant radiochemotherapy primary chemotherapy palliative chemotherapy targeted treatment
